Compare Paycom Software Inc (PAYC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs BIO-TECHNE Corp — how do they compare? Paycom Software Inc trades at $228.76 (market cap $10.36B), while BIO-TECHNE Corp trades at $72.47 (market cap $11.36B). The key difference: Paycom Software Inc and BIO-TECHNE Corp are close in size by market cap, and Paycom Software Inc pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and BIO-TECHNE Corp for 63 Days on average.
| PAYC | TECH | |
|---|---|---|
Market Cap | $10.36B | $11.36B |
Volume | 666,294 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $240.52 | $72.61 |
52-Week Low | $113.59 | $43.31 |
Typical Hold Time | 84 Days | 63 Days |
Enterprise Value | $11.15B | $11.39B |
Dividend Yield | 0.65% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $230.80, up 3.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 10% revenue growth in Q2 2026, 83.67% gross margins, and consistent earnings beats. Recent institutional buying and positive analyst coverage support the stock's upward trajectory, though valuation multiples remain elevated compared to industry peers.
Outlook remains positive with raised 2026 guidance targeting 7-8% revenue growth and 46% EBITDA margins. Key risks include competitive pressures in payroll software and market volatility. The consensus price target of $207.75 suggests potential downside from current levels despite strong operational performance.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
